Goldman Sachs analyst Andrea Newkirk initiated coverage of Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. The firm says Kymera is an early, clinical-stage biopharmaceutical company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Gilead estimates Q2 acquired IPR&D expenses of $61M
- Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
- Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships
- Kymera Therapeutics assumed with an Overweight at Morgan Stanley
- Kymera Therapeutics management to meet with B. Riley